Englander Institute for Precision Medicine

Publications

Found 820 results
Author Title Type [ Year(Asc)]
2023
Hegewisch-Solloa E, Melsen JE, Ravichandran H, Rendeiro AF, Freud AG, Mundy-Bosse B, Melms JC, Eisman SE, Izar B, Grunstein E et al..  2023.  Mapping human natural killer cell development in pediatric tonsil by imaging mass cytometry and high-resolution microscopy.. bioRxiv.
Pandey RS, Arnold M, Batra R, Krumsiek J, Kotredes KP, Garceau D, Williams H, Sasner M, Howell GR, Kaddurah-Daouk R et al..  2023.  Metabolomics profiling reveals distinct, sex-specific signatures in the serum and brain metabolomes in the mouse models of Alzheimer's disease.. bioRxiv.
López-Otín C, Pietrocola F, Roiz-Valle D, Galluzzi L, Kroemer G.  2023.  Meta-hallmarks of aging and cancer.. Cell Metab. 35(1):12-35.
Huang SH, Sartorello G, Shen P-T, Xu C, Elemento O, Shvets G.  2023.  Metasurface-enhanced infrared spectroscopy in multiwell format for real-time assaying of live cells.. Lab Chip. 23(9):2228-2240.
Pulcrano S, De Gregorio R, De Sanctis C, Volpicelli F, Piscitelli RMaria, Speranza L, Perrone-Capano C, di Porzio U, Caiazzo M, Martini A et al..  2023.  miR-218 Promotes Dopaminergic Differentiation and Controls Neuron Excitability and Neurotransmitter Release through the Regulation of a Synaptic-Related Genes Network.. J Neurosci. 43(48):8104-8125.
Kepp O, Liu P, Kroemer G, Galluzzi L.  2023.  A mitochondrial checkpoint to adaptive anticancer immunity.. Oncoimmunology. 12(1):2271693.
Soler-Agesta R, Anel A, Galluzzi L.  2023.  Mitochondrial control of antigen presentation in cancer cells.. Cancer Cell. 41(11):1849-1851.
Marchi S, Guilbaud E, Tait SWG, Yamazaki T, Galluzzi L.  2023.  Mitochondrial control of inflammation.. Nat Rev Immunol. 23(3):159-173.
Schweickart A, Batra R, Neth BJ, Martino C, Shenhav L, Zhang AR, Shi P, Karu N, Huynh K, Meikle PJ et al..  2023.  A Modified Mediterranean Ketogenic Diet mitigates modifiable risk factors of Alzheimer's Disease: a serum and CSF-based metabolic analysis.. medRxiv.
Maura F, Ziccheddu B, Xiang JZ, Bhinder B, Rosiene J, Abascal F, Maclachlan KH, Eng KWha, Uppal M, He F et al..  2023.  Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg Cells.. Blood Cancer Discov. 4(3):208-227.
Benedetti E, Liu EMinwei, Tang C, Kuo F, Buyukozkan M, Park T, Park J, Correa F, A Hakimi A, Intlekofer AM et al..  2023.  A multimodal atlas of tumour metabolism reveals the architecture of gene-metabolite covariation.. Nat Metab. 5(6):1029-1044.
Scarpa JR, Elemento O.  2023.  Multi-omic molecular profiling and network biology for precision anaesthesiology: a narrative review.. Br J Anaesth. 131(1):26-36.
Song W-M, Elmas A, Farias R, Xu P, Zhou X, Hopkins B, Huang K-L, Zhang B.  2023.  Multiscale protein networks systematically identify aberrant protein interactions and oncogenic regulators in seven cancer types.. J Hematol Oncol. 16(1):120.
Mlynarczyk C, Teater M, Pae J, Chin CR, Wang L, Arulraj T, Barisic D, Papin A, Hoehn KB, Kots E et al..  2023.   mutation yields supercompetitive B cells primed for malignant transformation.. Science. 379(6629):eabj7412.
Hussain M, Sternberg CN, Efstathiou E, Fizazi K, Shen Q, Lin X, Sugg J, Steinberg J, Noerby B, De Giorgi U et al..  2023.  Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial.. J Urol. 209(3):532-539.
Altorki NK, Walsh ZH, Melms JC, Port JL, Lee BE, Nasar A, Spinelli C, Caprio L, Rogava M, Ho P et al..  2023.  Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial.. Nat Commun. 14(1):8435.
Bamias A, Merseburger A, Loriot Y, James N, Choy E, Castellano D, Lopez-Rios F, Calabrò F, Kramer M, de Velasco G et al..  2023.  New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors.. J Immunother Cancer. 11(1)
Barnes J, Brendel M, Gao VR, Rajendran S, Kim J, Li Q, Malmsten JE, Sierra JT, Zisimopoulos P, Sigaras A et al..  2023.  A non-invasive artificial intelligence approach for the prediction of human blastocyst ploidy: a retrospective model development and validation study.. Lancet Digit Health. 5(1):e28-e40.
Fornarini G, Rebuzzi SE, Buti S, Rescigno P, Merseburger A, Sternberg CN, De Giorgi U, Basso U, Maruzzo M, Giannatempo P et al..  2023.  A novel immunotherapy prognostic score for patients with pretreated advanced urInary TrAct CArcinoma from the subgroup analysis of the SAUL study: the ITACA Score.. Minerva Urol Nephrol. 75(3):308-318.
Bhardwaj P, Iyengar NM, Zahid H, Carter KM, Byun DJun, Choi MHo, Sun Q, Savenkov O, Louka C, Liu C et al..  2023.  Obesity promotes breast epithelium DNA damage in women carrying a germline mutation in .. Sci Transl Med. 15(684):eade1857.
Lauritsen J, Sauvé N, Tryakin A, Jiang DMaria, Huddart R, Heng DYC, Terbuch A, Winquist E, Chovanec M, Hentrich M et al..  2023.  Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: an analysis of the IGCCCG Update database.. Br J Cancer. 129(11):1759-1765.
Vanpouille-Box C, Galluzzi L.  2023.  p53 regulates the mitochondrial immune checkpoint.. Trends Immunol. 44(4):245-247.
Li Y, Porta-Pardo E, Tokheim C, Bailey MH, Yaron TM, Stathias V, Geffen Y, Imbach KJ, Cao S, Anand S et al..  2023.  Pan-cancer proteogenomics connects oncogenic drivers to functional states.. Cell. 186(18):3921-3944.e25.
Rowdo FPMadorsky, Xiao G, Khramtsova GF, Nguyen J, Olopade OI, Martini R, Stonaker B, Boateng R, Oppong JK, Adjei EK et al..  2023.  Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.. bioRxiv.
Askari E, Moghadam SZarehparva, Wild D, Delpassand E, Baldari S, Nilica B, Hartrampf PE, Kong G, Grana CMaria, Walter MAlexander et al..  2023.  Peptide Receptor Radionuclide Therapy in Merkel Cell Carcinoma: A Comprehensive Review.. J Nucl Med Technol. 51(1):22-25.